grow
incid
new
viral
diseas
increasingli
frequent
viral
epidem
strain
therapeut
prevent
measur
high
mutabl
viral
gene
put
addit
strain
development
effort
given
high
cost
time
requir
new
drug
develop
vaccin
remain
viabl
altern
tradit
techniqu
liveattenu
inactiv
vaccin
danger
allergen
reaction
other
peptid
vaccin
last
sever
year
begun
look
appropri
altern
econom
afford
requir
less
time
develop
hold
promis
multival
dosag
develop
bioinformat
proteom
immunogenom
structur
biolog
scienc
spur
growth
vaccinom
comput
assist
approach
serv
identifi
suitabl
peptid
target
eventu
develop
vaccin
minireview
give
brief
overview
recent
trend
comput
assist
vaccin
develop
emphasi
primari
select
procedur
probabl
peptid
candid
vaccin
develop
viral
diseas
affect
million
peopl
worldwid
annual
dengu
viru
diseas
affect
million
peopl
global
fatal
rotaviru
infect
two
million
children
five
year
age
die
season
influenza
epidem
caus
sever
ill
three
five
million
peopl
quarter
half
million
death
name
drug
vaccin
avail
mani
viral
diseas
high
mutat
rate
characterist
viral
genom
render
mani
rapidli
obsolet
thu
continu
hunt
new
drug
vaccin
compound
fact
new
virus
come
attack
human
host
higher
frequenc
mutabl
viral
sequenc
rapidli
render
exist
drug
vaccin
obsolet
among
latest
incid
viral
epidem
one
may
recal
influenza
type
hemagglutinin
subtyp
neuraminidas
subtyp
swine
flu
pandem
sar
sever
acut
respiratori
syndrom
epidem
mer
middl
east
respiratori
syndrom
epidem
ebola
epidem
case
death
report
march
dengu
epidem
india
zika
viru
epidem
south
america
process
drug
discoveri
bench
market
long
expensivemor
like
year
close
two
billion
dollar
sinc
viral
epidem
die
within
one
year
two
process
would
imposs
new
virus
drug
cur
vaccin
prevent
mean
attract
altern
develop
cost
rel
lower
standard
practic
util
inactiv
attenu
virus
purpos
fraught
problem
includ
allergen
reaction
tradit
vaccin
attenu
vaccin
also
known
liveattenu
vaccin
creat
alter
genom
becom
less
virul
harmless
vaccin
measl
mump
rubella
other
creat
way
good
success
rate
sometim
revert
virul
statu
mutat
anoth
convent
vaccin
inactiv
vaccin
produc
kill
origin
viru
heat
chemic
introduc
remain
viru
shell
host
bodi
shell
virion
capsid
properli
manufactur
retain
enough
origin
capsid
elicit
immun
respons
varieti
polio
vaccin
influenza
vaccin
produc
way
improp
manufactur
retain
origin
viru
caus
infect
problem
need
booster
dose
etc
well
third
type
vaccin
manufactur
origin
viru
virallik
particl
vlp
vaccin
vlp
construct
surfac
protein
selfassembl
viruslik
structur
mimic
origin
viru
structur
elicit
strong
immun
respons
adjuv
first
vlp
vaccin
licens
grant
us
food
drug
administr
hepat
b
viru
sinc
two
licens
grantedfor
human
papillomaviru
hepat
e
viru
cater
fast
develop
safer
product
new
paradigm
take
shape
vaccin
develop
avail
genom
data
advanc
bioinformat
technolog
comput
resourc
increas
understand
immun
respons
immunogenet
move
develop
away
one
size
fit
product
prescript
one
possibl
orient
toward
individu
commun
popul
specif
exist
new
vaccin
design
deem
increas
necess
hypervari
virus
like
coronaviru
influenza
like
tradit
vaccin
fail
cope
chang
ration
design
vaccin
scienc
revers
vaccinolog
yet
nascent
cultur
pointer
toward
futur
vaccin
develop
peptid
vaccin
belong
one
new
categori
idea
scan
viral
genom
protein
antigen
elicit
immun
respons
synthes
peptid
vaccin
focus
approach
precis
locat
epitop
region
within
antigen
util
elicit
immun
respons
recent
advanc
technolog
bioinformat
field
enabl
computerbas
approach
purpos
peptid
vaccin
use
anim
time
first
report
success
virul
canin
paroviru
stimul
develop
peptid
vaccin
diseas
malaria
classic
swine
fever
viru
anim
vaccin
human
variou
stage
trial
recombin
dna
technolog
nake
dna
use
induc
immun
respons
viru
infect
synthet
peptid
vaccin
approach
peptid
vaccinolog
prompt
adapt
along
similar
line
develop
vaccin
new
virus
niaid
nation
institut
allergi
infecti
diseas
nih
nation
institut
health
usa
taken
case
zika
viru
urgenc
pursu
sever
path
includ
dnabas
vaccin
use
strategi
similar
flaviviru
vaccin
west
nile
viru
liveattenu
version
zika
viru
genet
engin
version
vesicular
stomat
viru
present
lab
bench
process
peptid
vaccin
determin
involv
identif
appropri
viral
protein
peptid
segment
accord
chosen
criteria
ensur
adequ
hydrophil
select
peptid
epitop
potenti
peptid
segment
cellular
humor
immun
respons
test
elimin
autoimmun
threat
come
consider
suitabl
carrier
question
shelf
life
logist
measur
occasion
multipl
peptid
one
viral
infect
combin
cluster
multipl
antigen
peptid
map
immun
map
highli
immunogen
substitut
multival
vaccin
combin
sever
select
peptid
figur
give
concis
flow
chart
peptid
vaccin
design
hypothesi
peptid
vaccin
spawn
mani
experi
vivo
valid
sometim
straight
bioinformat
studi
wet
lab
brossart
et
al
show
patient
advanc
breast
ovarian
cancer
could
benefit
peptid
vaccin
gene
human
encod
cell
surfac
associ
mucin
ludewig
et
al
found
protect
antivir
antitumor
immun
respons
peptid
antigen
base
vaccin
lymphocyt
choriomening
viru
administ
intraderm
liao
et
al
huazhong
univers
scienc
technolog
predict
epitop
human
papillomaviru
protein
peptid
vaccin
candid
use
bioinformat
studi
verifi
administ
peptid
along
cpg
short
singlestrand
synthet
dna
moleculecytosin
triphosph
deoxynucleotid
c
phosphodiest
link
p
follow
guanin
triphosph
deoxynucleotid
g
adjuv
inject
muscl
mous
model
strong
cellmedi
immun
cmi
protect
mice
tumor
growth
seen
likewis
rojascaraballo
et
al
determin
sever
bcell
tcell
epitop
region
fasciola
hepatica
viru
protein
amino
acid
sequenc
use
bioinformat
analys
immun
balbc
mice
albino
laboratorybr
strain
hous
mous
wide
use
anim
experi
synthet
peptid
show
high
level
protect
diseas
phase
trial
multival
peptid
vaccin
nonsmal
cell
lung
cancer
found
vaccin
use
mixtur
four
peptid
safe
capabl
gener
strong
tcell
respons
question
shelf
life
logist
measur
occasion
multipl
peptid
one
viral
infect
combin
cluster
multipl
antigen
peptid
map
immun
map
highli
immunogen
substitut
multival
vaccin
combin
sever
select
peptid
figur
give
concis
flow
chart
peptid
vaccin
design
hypothesi
peptid
vaccin
spawn
mani
experi
vivo
valid
sometim
straight
bioinformat
studi
wet
lab
brossart
et
al
show
patient
advanc
breast
ovarian
cancer
could
benefit
peptid
vaccin
gene
human
encod
cell
surfac
associ
mucin
ludewig
et
al
found
protect
antivir
antitumor
immun
respons
peptid
antigen
base
vaccin
lymphocyt
choriomening
viru
administ
intraderm
liao
et
al
huazhong
univers
scienc
technolog
predict
epitop
human
papillomaviru
protein
peptid
vaccin
candid
use
bioinformat
studi
verifi
administ
peptid
along
cpg
short
singlestrand
synthet
dna
moleculecytosin
triphosph
deoxynucleotid
c
phosphodiest
link
p
follow
guanin
triphosph
deoxynucleotid
g
adjuv
inject
muscl
mous
model
strong
cellmedi
immun
cmi
protect
mice
tumor
growth
seen
likewis
rojascaraballo
et
al
determin
sever
bcell
tcell
epitop
region
fasciola
hepatica
viru
protein
amino
acid
sequenc
use
bioinformat
analys
immun
balbc
mice
albino
laboratorybr
strain
hous
mous
wide
use
anim
experi
synthet
peptid
show
high
level
protect
diseas
phase
trial
multival
peptid
vaccin
nonsmal
cell
lung
cancer
found
vaccin
use
mixtur
four
peptid
safe
capabl
gener
strong
tcell
respons
recent
advanc
bioinformat
proteom
immunoinformat
structur
biolog
other
led
vaccinom
revers
vaccinolog
novel
approach
gener
new
vaccin
realm
drug
develop
scientif
technolog
advanc
led
power
inhibitor
like
relenza
influenza
develop
neuraminidas
crystal
structur
aid
acquir
immun
defici
syndrom
drug
aegeneras
viracept
develop
structurebas
design
approach
advanc
peptidebas
vaccin
come
better
understand
immunogenet
antigen
mhc
major
histocompat
complex
bind
peptid
hla
human
leukocyt
antigen
bind
motif
other
nih
websit
databas
clinic
studi
human
particip
list
peptid
vaccin
variou
phase
trial
develop
vast
major
relat
cancer
includ
recombin
protein
compris
nine
conserv
peptid
influenza
b
antiinfluenza
peptid
vaccin
phase
iib
studi
phase
studi
anoth
influenza
vaccin
multipeptid
mix
adjuv
newli
discov
conserv
segment
protein
augment
bodi
natur
immun
broader
rationallydesign
immun
induc
phase
studi
mayo
clinic
combin
vaccin
therapi
chemotherapi
cyclophosphamid
expect
higher
effici
kill
tumor
cell
ongo
phase
studi
us
nation
cancer
institut
peptid
vaccin
treat
patient
metastat
cancer
respond
previou
therapi
among
other
singluff
fact
report
peptid
vaccin
shown
good
promis
case
mani
cancer
mixtur
peptid
evok
good
immun
respons
patient
tabl
list
peptid
vaccin
project
variou
phase
clinic
trial
larg
number
trial
undertaken
mani
commerci
firm
academicand
healthrel
institut
suggest
potenti
interest
peptid
vaccin
phase
ii
identifi
rise
interest
peptid
vaccin
drawn
mani
review
may
refer
variou
aspect
promis
field
interest
review
differ
approach
one
import
step
process
design
peptid
vaccin
viz
choic
protein
peptid
segment
crucial
first
step
process
good
reliabl
result
firstli
requir
adequ
molecular
level
data
viru
second
reliabl
techniqu
analyz
data
identifi
sequenc
segment
interest
vaccin
develop
purpos
computerbas
methodolog
primari
modu
operandi
remark
recent
articl
review
elabor
bioinformat
analyt
approach
use
pinpoint
peptid
segment
choic
growth
web
access
expand
entri
biolog
databas
numer
server
develop
variou
purpos
silico
screen
genom
inform
reduc
workload
experimentalist
focus
goal
number
serverbas
tool
avail
predict
probabl
antigen
site
success
depend
accuraci
predict
approach
use
sequenc
align
identifi
antigen
approach
limit
sinc
protein
may
addit
delet
andor
substitut
similar
function
within
overal
structur
sequenc
method
obvious
predict
new
hitherto
unrecogn
antigen
given
rise
alignmentfre
approach
vaxijen
base
auto
crosscovari
allow
antigen
classif
sole
base
physicochem
properti
protein
collect
bacteri
viral
tumor
protein
dataset
sever
web
server
design
predict
tcell
bcell
epitop
target
humoraland
cellbas
immun
respons
popular
web
server
includ
iedb
immun
epitop
databas
analysi
resourc
curat
databas
experiment
character
immun
epitop
compar
queri
peptid
abcpr
artifici
neural
network
base
bcell
epitop
predict
server
use
artifici
neural
network
program
train
set
known
bcell
epitop
nonbcel
ie
random
peptid
analyz
queri
peptid
predict
likelihood
bcell
epitop
predivac
predict
softwar
vaccin
design
develop
recent
predict
tcell
epitop
test
highaffin
hla
class
ii
peptid
bind
found
compar
well
sever
webaccess
method
hla
class
ii
peptidebind
predict
support
vector
machin
base
method
predict
promiscu
mhc
class
ii
bind
peptid
oani
et
al
investig
comput
approach
design
peptid
vaccin
human
coronaviru
hcov
caus
upper
respiratori
tract
infect
led
sar
epidem
earli
centuri
present
strain
hcov
spike
protein
vaxijen
server
select
one
highest
antigen
index
next
analysi
epitopepredict
tcell
respons
select
five
peptid
highest
epitop
score
protein
base
result
netctl
server
predict
ctl
cytotox
lymphocyt
epitop
protein
sequenc
identifi
mer
epitop
ksstgfvyf
amino
acid
sequenc
nonapeptid
chain
contain
follow
sequenc
nine
amino
acid
left
right
lysin
serin
serin
threonin
glycin
phenylalanin
valin
tyrosin
phenylalanin
interact
mhci
allel
high
affin
next
determin
conserv
bcell
epitop
iedb
immun
epitop
databas
server
allergen
allerhunt
tool
found
epitop
conserv
allergenc
score
well
threshold
valu
next
step
molecular
dock
analysi
select
peptid
hlab
found
show
good
bind
bcell
epitop
search
use
kolaskar
tongaonkar
antigen
predict
method
show
seven
region
high
antigen
score
reduc
three
solvent
access
determin
emini
surfac
access
option
iedb
analysi
resourc
analysi
bprep
epitop
predict
server
linear
bcell
epitop
author
conclud
peptid
gpssqpi
heptapeptid
conta
amino
acid
left
right
glycin
prolin
serin
serin
glutamin
prolin
tyrosin
capabl
induc
desir
immun
respons
use
bcell
epitop
similar
strategi
use
islam
et
al
search
conserv
highscor
epitop
region
protein
chikungunya
viru
sequenc
align
select
strain
viru
determin
rel
immun
respons
propens
use
differ
web
server
enabl
identifi
stretch
conserv
region
glycoprotein
show
heighten
tcell
bcell
immun
potenti
molecular
dock
studi
show
good
bind
epitop
hla
chakraborti
et
al
approach
peptid
identif
dengu
viru
slightli
differ
way
determin
consensu
sequenc
dengu
viru
envelop
glycoprotein
nine
conserv
segment
amino
acid
segment
sequenc
align
complet
envelop
protein
sequenc
four
serotyp
dengu
viru
retain
segment
conserv
amino
acid
within
segment
exceed
next
step
discard
hydrophob
exceed
impli
reduc
propens
surfac
exposur
therefor
antigenantibodi
interact
ensur
retain
high
antigen
determin
web
server
like
vaxijen
highest
antigen
per
vaxijen
low
hydrophob
score
peptid
faghlkcrl
amino
acid
sequenc
read
left
right
phenylalanin
alanin
glycin
histidin
leucin
lysin
cystein
arginin
leucin
six
total
peptid
recommend
peptid
vaccin
plant
virus
alfalfa
mosaic
viru
cabbag
leaf
curl
viru
identifi
help
neural
network
gomas
et
al
neural
network
train
c
termin
known
epitop
use
predict
mhc
class
ii
bind
viral
protein
peptid
segment
high
antigen
epitop
properti
predict
bind
properti
gener
strong
immun
respons
antigen
implement
design
synthet
peptid
vaccin
mathemat
approach
character
biomolecular
sequenc
compar
new
area
sequenc
analysi
research
enabl
alignmentfre
tool
rapid
scan
larg
number
sequenc
time
determin
area
similar
dissimilar
proven
especi
use
virusrel
studi
numer
measur
aid
variou
studi
viru
transmiss
path
prognosi
possibl
reassort
bird
flu
phylogenet
analys
ghosh
et
al
use
alignmentfre
sequenc
descriptor
identifi
conserv
peptid
viral
protein
sequenc
method
scan
protein
sequenc
window
amino
acid
requir
consid
sequenc
descriptor
window
posit
protein
sequenc
determin
region
least
variabl
region
therefor
impli
evolutionari
pressur
retain
structur
consequ
rel
mostli
conserv
conserv
stretch
analyz
hydrophil
determin
surfac
situat
peptid
confirm
protein
structur
next
step
determin
one
tcell
bcell
epitop
follow
retain
peptid
test
autoimmun
threat
remain
peptid
pass
test
report
good
candid
act
peptid
vaccin
sarkar
et
al
analysi
hemagglutinin
humaninfect
influenza
china
determin
sever
target
region
design
peptid
vaccin
viru
also
abl
show
molecular
dock
analys
two
mutat
conserv
region
receptor
bind
site
characterist
humaninfect
natur
import
consider
computerassist
drug
vaccin
design
power
comput
measur
storag
capac
memori
process
speed
recent
exercis
calcul
sequenc
descriptor
genom
sequenc
zika
viru
base
long
matrixori
numer
character
model
time
taken
laptop
comput
gb
ram
gigabyt
random
access
memori
dual
core
processor
still
long
abandon
comput
model
process
power
machin
program
effici
factor
consid
take
approach
determin
peptid
vaccin
target
context
may
worthwhil
consid
whether
techniqu
quantit
structureact
relationship
qsar
extend
search
suitabl
peptid
mathemat
biodescriptor
deriv
toxicoproteom
map
chemodescriptor
use
predict
toxic
could
conceiv
extend
cover
epitop
bind
integr
qsar
develop
use
chemodescriptor
ligand
biodescriptor
cover
transcript
translat
posttransl
modif
process
connect
structur
inform
dnarna
sequenc
rna
secondari
structur
protein
tertiari
structur
may
use
predict
paramet
new
entiti
found
use
numer
indic
deriv
molecular
graphic
qsar
studi
simpler
work
protein
structur
could
extend
optim
search
surfac
antigen
primari
requir
analysi
viral
protein
select
segment
suitabl
vaccin
target
adequ
data
molecular
sequenc
data
need
purpos
review
nucleotid
sequenc
data
protein
sequenc
data
structur
associ
protein
data
use
further
analysi
would
compris
mhc
bind
data
epitop
data
etc
case
mani
virus
enough
data
repositori
eg
data
avail
abund
main
surfac
protein
influenza
virus
rotaviru
sequenc
data
surfac
protein
understand
less
structur
data
virus
still
adequ
vari
data
purpos
vaccin
design
howev
mani
virus
understand
adequ
data
avail
recentlyemerg
zika
viru
ebola
viru
matter
surfac
pathogen
epidem
form
howev
case
eg
papillomaviru
data
avail
special
databas
data
could
made
avail
wide
least
primari
data
repres
gener
databas
like
genbank
wider
dissemin
could
lead
research
perhap
new
insight
point
note
qualiti
data
maintain
high
qualiti
data
integr
prime
requisit
numer
analys
erron
data
throw
comput
gear
caus
loss
preciou
time
deal
infect
epidem
proport
case
zika
genom
data
notic
rather
larg
number
ambigu
unconfirm
base
nucleotid
sequenc
caus
erron
result
sensit
case
review
comput
aspect
design
new
gener
vaccin
import
understand
translat
bioinformaticallyidentifi
peptid
work
vaccin
involv
mani
step
one
major
step
identif
adjuv
presenc
proper
adjuv
greatli
enhanc
immun
respons
adjuvnt
found
integr
peptid
vaccin
also
vlp
vaccin
cerverix
use
adjuv
almeida
et
al
report
strong
immun
respons
use
gold
nanoparticl
adjuv
ovalbumin
peptid
antigen
lead
antitumor
activ
anoth
problem
take
note
possibl
peptid
fold
therefor
sharpli
reduc
immun
activ
storag
transport
factor
need
investig
peptid
vaccin
made
readi
market
deliber
far
outsid
scope
review
computerassist
drug
vaccin
discoveri
rel
new
field
mani
aspect
still
progress
develop
mani
webassist
platform
analysi
variou
aspect
process
select
final
determin
immun
respons
gener
caus
agent
autom
sever
task
howev
method
initi
screen
probabl
vaccin
candid
matter
choic
pure
silico
techniqu
coupl
biodescriptor
mathemat
method
still
rel
novel
overal
wetlab
experiment
necessari
prove
viabil
new
approach
howev
rel
advantag
peptid
vaccin
formul
term
speed
cost
develop
frequent
incid
viral
epidem
new
varieti
viral
diseas
make
pursuit
ration
design
peptid
vaccin
import
altern
endeavor
computerassist
approach
appear
show
good
promis
peptid
vaccin
identif
strategi
